FDA drives consent decree with H&P/Triad

The other shoe has dropped. H&P Industries, whose plant in Hartland, WI, was idled recently following a product seizure, is now operating under a consent decree with the FDA.

The decree allows H&P, whose products are distributed by Triad, to continue working on the comprehensive action plan it filed in January to improve quality systems, according to a company statement. The plan "identifies procedures that will help provide additional assurance of product quality to the FDA."

President Eric Haertle, who recently relinquished his COO role at H&P, says his company is "fully committed" to addressing the agency's concerns. He also hired an independent expert to inspect the facility, make recommendations and direct H&P on a work plan. The FDA's approval of the work plan will green-light H&P to resume manufacturing.  

The company anticipates at least five years of consent decree operations.

H&P was the late-February recipient of a 46-count FDA Form 483 inspection report and was shut down by the agency in April after U.S. Marshals seized $6 million in products and inventory. The actions followed three recalls of sterile and non-sterile alcohol wipes and swabs possibly contaminated with bacteria.

- see the H&P/Triad announcement

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.